Coagulation, anticoagulation and pancreatic carcinoma

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 8, 2008, Pages 445-455

  Nakchbandi, Inaam A ^a,b   Löhr, J Matthias ^c,d  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; ANTIVITAMIN K; CERTOPARIN; CISPLATIN; DALTEPARIN; ENOXAPARIN; FIBRINOGEN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; HEPARIN; HIRUDIN; K RAS PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN C; NADROPARIN; PLASMINOGEN ACTIVATOR; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROTEIN C; PROTEIN P53; PROTEIN S; THROMBIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; WARFARIN;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LOW DRUG DOSE; METASTASIS POTENTIAL; NONHUMAN; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; HEPARIN; HUMANS; PANCREATIC NEOPLASMS; RECURRENCE; THROMBOEMBOLISM; WARFARIN;

EID: 49249121493     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1184     Document Type: Review

References (88)

1. Moore MJ et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966
2. Löhr M (2006) Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 3: 236-237
3. Trousseau A (1865) Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu. Paris: Bailliere JB 3: 654-712
4. Bariety M (1947) Trousseau, 1801-67. Geneva: Mazenod, 234-235
5. Khorana AA and Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5: 655-663
6. Sproul E (1938) Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Amer J Cancer 34: 566-585
7. Pinzon R et al. (1986) Pancreatic carcinoma and Trousseau's syndrome: Experience at a large cancer center. J Clin Oncol 4 509-514
8. Virchow RLK (1856) Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt, Meidinger: Sohn & Co. (Reprint edition: Virchow R (1998) Thrombosis and Emboli (1846-1856). AG Matzdorff, WR Bell, transl, Canton, MA: Science History Publications
9. Brotman DJ et al. (2004) Virchow's triad revisited. South Med J 97: 213-214
10. Haas SL et al. (2006) Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12: 4843-4849
11. Khorana AA et al. (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13: 2870-2875
12. Wojtukiewicz MZ et al. (2000) Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 97: 335-342
13. Rudroff C et al. (2002) Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 19: 181-189
14. Wojtukiewicz M.Z et al. (2001) Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 86: 1416-1420
15. Kakkar A et al. (1995) Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82: 1101-1104
16. Nitori N et al. (2005) Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 11: 2531-2539
17. Ueda C et al. (2001) Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 36: 848-850
18. Lindahl AK et al. (1992) Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer 70: 2067-2072
19. Wojtukiewicz M et al. (2003) Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 90: 140-146
20. Chaturvedi P et al. (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5: 309-320
21. Lindahl AK et al. (1993) Increased plasma thrombomodulin in cancer patients. Thromb Haemost 69: 112-114
22. Marguerie GA et al. (1984) The platelet-fibrinogen interaction. Evidence for proximity of the A alpha chain of fibrinogen to platelet membrane glycoproteins IIb/III. Eur J Biochem 139: 5-11
23. Isenberg JS et al. (2008) Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111: 613-623
24. Tobita K et al. (2002) Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 21: 1189-1195
25. Wahrenbrock M (2003) Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112: 853-862
26. Kakkar AK (1998) A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 28: 1-6
27. Andren-Sandberg A et al. (1992) Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 69: 2884-2887
28. Jesnowski R et al. (2007) Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells. Neoplasia 9: 136-146
29. Yu JL et al. (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 105: 1734-1741
30. Redston MS et al. (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homacopolymer tracts in DNA microdeletions. Cancer Res 54: 3025-3033
31. Allgayer H et al. (1999) Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 80: 1884-1891
32. Fernandez PM et al. (2004) Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 30: 31-44
33. Ruf W and Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32 (Suppl 1): S61-S68
34. Tsopanoglou NE and Maragoudakis ME (2004) Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 30: 63-69
35. Hobbs JE et al. (2007) Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 120 (Suppl 2): S13-S21
36. Alvarez RH et al. (2006) Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81: 1241-1257
37. Hwang RF et al. (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544
38. Löhr M et al. (2001) Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61: 550-555
39. Kleeff J et al. (2007) Pancreatic cancer microenvironment. Int J Cancer 121: 699-705
40. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: E26-e31
41. Albo D et al. (1999) Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg 3: 411-417
42. Fareed D et al. (2004) Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: Pathophysiologic implications. Clin Appl Thromb Hemost 10: 357-364
43. Scarpati EM and Sadler JE (1989) Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 264: 20705-20713
44. Esposito I et al. (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57: 630-636
45. Rudroff C et al. (2001) Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. Eur J Surg Oncol 27: 472-476
46. Gunji Y and Gorelik E (1988) Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48: 5216-5221
47. Palumbo JS et al. (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96 3302-3309
48. He Y et al. (2007) Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 13: 3115-3124
49. Qian X et al. (1997) Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 235: 403-412
50. Qian X et al. (2001) Expression of thrombospondin-1 in human pancreatic adenocarcinomas: Role in matrix metalloproteinase-9 production. Pathol Oncol Res 7: 251-259
51. Palumbo JS et al. (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105: 178-185
52. Monreal, M et al. (1991) Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 67: 541-545
53. Prandoni P et al. (1992) Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327: 1128-1133
54. Monreal M et al. (1997) Occult cancer in patients with venous thromboembolism: Which patients, which cancers. Thromb Haemost 78: 1316-1318
55. White RH et al. (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165: 1782-1787
56. Sorensen HT et al. (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343: 1846-1850
57. Iodice S et al. (2008) Venous thromboembolic events and organ-specific occult cancers: A review and meta-analysis. J Thromb Haemost 6: 781-788
58. Mandala M et al. (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18: 1660-1665
59. Khorana AA et al. (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24: 484-490
60. Chew HK et al. (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464
61. Hirsh J et al. (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107: 1692-1711
62. Hirsh J et al. (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (Suppl 1): S64-S94
63. Norrby K (2006) Low-molecular-weight heparins and angiogenesis. Apmis 114: 79-102
64. Miller GJ et al. (2004) Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2: 2107-2114
65. Folkman J et al. (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719-725
66. Pross M et al. (2004) Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study. Int J Colorectal Dis 19: 143-146
67. Schwalke MA et al. (1990) Effects of prostacyclin on hepatic metastases from human pancreatic cancer in the nude mouse. J Surg Res 49: 164-167
68. Schulman S and Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342: 1953-1958
69. Schulman S et al. (2006) Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 4: 734-742
70. Taliani MR et al. (2003) Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 1: 1730-1733
71. Zacharski LR et al. (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53: 2046-2052
72. Zacharski LR and Henderson WG (2002) A rebuttal: Vitamin K antagonists and cancer survival. Thromb Haemost 88: 173-175
73. Maurer LH et al. (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study. J Clin Oncol 15: 3378-3387
74. Kuderer NM et al. (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: Impact on survival and bleeding complications. Cancer 110: 1149-1161
75. Nakchbandi W et al. (2006) Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 41: 1095-1104
76. Nakchbandi W et al. Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. J Gastrointestin Liver Dis, in press
77. Lee AY et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 340: 146-153
78. Ruf W (2007) Tissue factor and PAR signaling in tumor progression. Thromb Res 120 (Suppl 2): S7-S12
79. Jung SP (2001) Inhibition of human angiogenesis with heparin and hydrocortisone. Angiogenesis 4: 175-186
80. Kiricuta I et al. (1973) Prophylaxis of metastases formation by unspecific immunologic stimulation associated with heparintherapy. Cancer 31: 1392-1396
81. Owen CA Jr (1982) Anticoagulant treatment of rats with Walker 256 carcinosarcoma. J Cancer Res Clin Oncol 104: 191-193
82. Green D et al. (1992) Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339 1476
83. Khorana AA et al. (2003) Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 23: 2110-2115
84. Lee AY et al. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23: 2123-2129
85. Icli F et al. (2007) Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 95: 507-512
86. von Delius S et al. (2007) Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 98: 434-439
87. Pelzer U et al. (2006) A prospective randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT CONKO 004). 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 24 (Suppl 18): S4110
88. Maraveyas A. Gemcitabine and dalteparin or gemcitabine alone for advanced pancreatic cancer (FRAGEM). [http://www.cancerhelp.org.uk/ trials/trials/] (to find, search for pancreatic cancer trials; accessed 16 May 2008)